Sierra Oncology is a clinical stage drug development company advancing targeted DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer. The company’s lead drug candidate, SRA737, is a highly selective, orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central…
Browsing: Ideas & Technologies
ProLung’s mission is to improve outcomes for potential lung cancer patients through early predictive technologies, provide cost savings to patients, payers, and providers, and to provide a fair return on investment to shareholders and other stakeholders. ProLung is committed to making a positive and significant impact on the healthcare community…
Fusion Genomics is a company that is working to advance molecular diagnostics through developing tests for pathogens that cause disease. They do this using proprietary technologies in combination with Next Generation Sequencing. Based in Vancouver, their ONETestTM products, in combination with their FUSIONCloudTM data analysis platform, allow for rapid identification…
Leap Therapeutics, Inc. (LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, recently reported financial results for the year ended December 31, 2016 and top-line progression-free survival (PFS) data. Earlier this year, Leap merged with Macrocure Ltd. and became listed on NASDAQ. The company’s most advanced clinical candidate, DKN-01, is a humanized monoclonal…
Genprex is a clinical-stage biopharmaceutical company developing targeted molecular therapies for cancer. The company is developing molecular therapies that control universal cancer pathways to unlock the unrealized potential of targeted cancer therapies, such as tyrosine kinase inhibitory drugs (TKIs). Genprex’s tumor suppression technologies are pan-kinase inhibitors that work to induce apoptosis (programmed…
Interpace Diagnostics is a company focused on the development and commercialization of molecular diagnostic tests aimed to optimize patient diagnosis and management. The company currently has three commercialized molecular tests: (1) PancraGen, for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts, (2) ThyGenX, for the diagnosis of thyroid…
Biocept is a diagnostic company that focuses on developing solutions aimed to optimize outcomes for cancer patients. Their most recent diagnostic comes in the form of a liquid biopsy, developed in an effort to alter the way in which doctors and other clinicians interpret blood samples of cancer patients. The…
Pieris Pharmaceuticals, Inc., a clinical stage biopharmaceutical company in Boston, is developing Anticalin-based drugs for the treatment of cancer, asthma, anemia and other conditions that show a high unmet medical need. Pieris’ drugs are created in a unique and transformative way, using immuno-oncology multi-specifics tailored for the tumor microenvironment, in…